Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
Lessons on the journey to commercialisation

Lessons on the journey to commercialisation

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

American Society of Hematology announces new grant program for biomedical research

American Society of Hematology announces new grant program for biomedical research

Cepheid launches new Xpert BCR-ABL Monitor test

Cepheid launches new Xpert BCR-ABL Monitor test

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

ASH report urges federal agencies to invest in 7 distinct areas of research

ASH report urges federal agencies to invest in 7 distinct areas of research

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path 2011 net loss increases to $2,363,344

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

East Asian BIM gene variant contributes to drug resistance in cancer

East Asian BIM gene variant contributes to drug resistance in cancer

CML patients can benefit from imatinib after unsuccessful interferon therapies

CML patients can benefit from imatinib after unsuccessful interferon therapies

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Kedem commences development of Gleevec to treat CML in children and adults

Kedem commences development of Gleevec to treat CML in children and adults

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting